

Cellmid Ltd

12:00 11 May 2016

Cellmid Ltd to benefit from data at Budapest Midkine Symposium

Cellmid Ltd's (ASX:CDY) Midkine (MK) antibody and protein assets have been supported by data recently presented at the Midkine Symposium in Budapest.

Clinicians and scientists from nine countries presented data on MK biology and its role in disease.

Findings confirmed Cellmid's clinical strategy for its portfolio of MK assets.

The symposium is expected to contribute to an adaptive clinical development path for MK antibodies.

Evidence also emerged during the symposium that MK is an important molecule in inter-organ signalling in a number of diseases.

Midkine Symposium key messages

While the presentations and discussions held during the symposium were made under confidentiality, some of the key messages included:

- Cellmid's N terminal binding MK antibodies were tested in a model and showed potential clinical application. They also showed enhanced bone fracture healing.
- Two of Cellmid's MK antibodies have shown tumour suppressing ability.
- New insights were presented into the structure of MK's binding with glycosaminoglycans.
- MK human diagnostic work by three separate groups included further understanding on urinary MK in prostate and bladder cancers and chronic kidney disease.

Background

Cellmid separates its business segments into consumer health which refers to its Advangen hair loss products and its MK assets.

Cellmid acquired the MK portfolio in 2008. Since the acquisition the MK intellectual property has been developed and achieved significant milestones as both the antibody and protein programs are nearing clinical development.

Cellmid has recently set up dedicated subsidiaries, Lynamid Limited and Kinera Limited as part of its clinical development plan to commercialise its MK antibody and protein assets.

Price: A\$0.5

Market Cap: A\$28.46M

1 Year Share Price Graph



Share Information

Code: CDY

Listing: ASX

52 week	High	Low
	0.8p	0.35p

Sector: Pharma & Biotech

Website: www.cellmid.com.au

Company Synopsis:

Cellmid Ltd (ASX:CDY) is listed on the Australian Securities Exchange.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

Lynamid will develop the company's large MK antibody portfolio, assessing likely therapeutic indications in fibrotic diseases and cancer.

Kinera will commercialise the company's MK protein assets in ischemic diseases, with a focus on chronic heart disease.

Analysis

Cellmid continue to develop therapeutic opportunities based on scientific merit for Cellmid's MK asset portfolio.

The company recently set up dedicated subsidiaries for its Cellmid assets to provide for a user friendly corporate and operational structure.

Being involved in industry specific global events such the Budapest Midkine Symposium is an important process for Cellmid as they market their MK portfolio to interested parties.

Upcoming events for Cellmid include:

- The planned June launch of the évolis® Professional range in Australia;
- An évolis® concept store in Tokyo planned to open in late CY2016; and
- Distribution partnerships to expand into the U.S. before the end of FY2016.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references

may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.